Rani Therapeutics shares surge 10.09% intraday after $1.09B Chugai collaboration and $60.3M financing announcement.

Rani Therapeutics Holdings, Inc. (RANI) surged 10.09% intraday following the announcement of a $1.09 billion collaboration with Chugai Pharmaceutical Co., covering multiple high-value therapeutics, including rare disease and immunology programs, and the completion of an oversubscribed $60.3 million private placement. The partnership with Chugai, a major Japanese pharma firm, signals strong validation of Rani’s oral biologics technology, while the funding boost enhances its development capacity. Analysts, including H.C. Wainwright, initiated a "Buy" rating with a $11 price target, and insider purchases by director Mir Imran further reinforced confidence. These developments collectively drove optimism around Rani’s pipeline and financial stability, aligning with the sharp intraday rally.